All In MedTech

FDA Clearance Tracker · P970008-S026

UROLOGIX TARGIS SYSTEM FOR THE TREATMENT OF BPH

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 16, 2005 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 16, 2005

Approved

Time to decision

111 days

Received Feb 25, 2005. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P970008-S026
Device name
UROLOGIX TARGIS SYSTEM FOR THE TREATMENT OF BPH
Applicant
Urologix, LLC
Applicant location
Plymouth, MN
Received
Feb 25, 2005
Decided
Jun 16, 2005
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P970008

Device type

Device class
Class III

Every decision under product code MEQ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A LONGER VERSION OF THE COOLED THERMOCATH MICROWAVE DELIVERY CATHETER. THE LONGER ANTENNA IS 37 MM COMPARED TO THE 28 MM ANTENNA IN THE CURRENTLY APPROVED COOLED THERMOCATH CATHETER. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME COOLED THERMOCATH 4.5+ AND IS INDICATED FOR MEN WITH PROSTATIC URETHRAL LENGTHS OF 4.5 CM OR GREATER.

Source documents

Other decisions for Urologix, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.